Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90937 | 0.82 | ITGB2 (0.50) | MAP3K14 | |
| SCHEMBL1224045 | 0.79 | ABCG2 (0.52) | ABCG2NQO2GSK3BGAAPKM | |
| SCHEMBL30521296 | 0.79 | ABCG2 (0.52) | ABCG2NQO2GSK3BGAAPKM | |
| SCHEMBL13255085 | 0.79 | ABCG2 (0.52) | ABCG2MAP3K14GAAPKMTSHR | |
| SCHEMBL436487 | 0.78 | MAP3K14 (0.46) | MAP3K14MAOB | |
| SCHEMBL15982282 | 0.77 | SMN1; SMN2 (0.56) | MAP3K14GAA | |
| SCHEMBL15982298 | 0.77 | SMN1; SMN2 (0.56) | MAP3K14GAA | |
| SCHEMBL15982274 | 0.77 | SMN1; SMN2 (0.56) | MAP3K14GAA | |
| SCHEMBL7594061 | 0.76 | ABCG2 (0.55) | ABCG2GSK3BPKMTSHREED | |
| SCHEMBL6569085 | 0.75 | MAP3K14 (0.36) | NQO2MAP3K14GAATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 622 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20110301217-A1 | Selective Glycosidase Inhibitors and Uses Thereof | SIMON FRASER UNIVERSITY (CA) | 2011-12-08 | — | — | US | claimed |
| EP-2344452-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Simon Fraser University (CA) | 2011-07-20 | — | — | EP | claimed |
| WO-2010037207-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2010-04-08 | — | — | WO | claimed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024059661-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-0291799-B1 | DIOXYALKYLENEARYL-DIHYDROPYRIDINES AND THEIR INTERMEDIARY COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0537517-A1 | Method for the preparation of 2,2-difluorobenzo(1,3)dioxolecarbaldehydes and intermediates | BAYER AG (DE) | 1993-04-21 | — | — | EP | disclosed |
| US-4886816-A | CARDIOTONIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0291799-A2 | Dioxyalkylenearyl-dihydropyridines and their intermediary compounds, process for their preparation and their use | BAYER AG (DE) | 1988-11-23 | — | — | EP | disclosed |
| US-4427666-A | 3,5-Dihalogeno-1,2-methylenedioxybenzene arthropodicide synergizing agents | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-24 | — | — | US | disclosed |
| EP-0004895-B1 | DICHLOROBENZODIOXOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNERGETIC AGENTS IN INSECTICIDAL AND ACARICIDAL COMPOSITIONS | BAYER AG (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4250187-A | 4,5-Dichloro-3-organo-1,2-methylenedioxy-benzene arthropodicide synergizing agents | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
| EP-0004895-A2 | Dichlorobenzodioxole derivatives, process for their preparation and their use as synergetic agents in insecticidal and acaricidal compositions | BAYER AG (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301217-A1 | Selective Glycosidase Inhibitors and Uses Thereof | ENGASE, OGA, GPI | ABCG2 451/4885NQO2 721/4885CYP19A1 3208/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | ABCG2 2630/4885NQO2 3201/4885CYP19A1 2627/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ABCG2 1774/4885NQO2 3760/4885CYP19A1 1759/4885 |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | AHR, ARNT, AIPL1 | ABCG2 310/4885NQO2 1597/4885CYP19A1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.